The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Design of RESILIENCE: A phase (Ph) III trial comparing capecitabine (CAP) in combination with sorafenib (SOR) or placebo (PL) for treatment (tx) of locally advanced (adv) or metastatic HER2-negative breast cancer (BC).
J. Baselga
No relevant relationships to disclose
L. S. Schwartzberg
Research Funding - Onyx
O. Petrenciuc
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
M. Shan
Employment or Leadership Position - Bayer
Stock Ownership - Bayer
W. J. Gradishar
No relevant relationships to disclose